Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001358605 | SCV003454663 | likely benign | not provided | 2024-03-17 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV004034506 | SCV004930044 | likely benign | Inborn genetic diseases | 2024-01-17 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
| Department of Pathology and Laboratory Medicine, |
RCV001358605 | SCV001554391 | uncertain significance | not provided | no assertion criteria provided | clinical testing | The COL7A1 p.Val211Ile variant was not identified in the literature nor was it identified in ClinVar or LOVD 3.0. The variant was identified in dbSNP (ID: rs557797952) and Cosmic (FATHMM prediction: pathogenic; score=0.7). The variant was also identified in control databases in 4 of 251358 chromosomes at a frequency of 0.000016 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: East Asian in 3 of 18392 chromosomes (freq: 0.000163) and South Asian in 1 of 30606 chromosomes (freq: 0.000033), but was not observed in the African, Latino, Ashkenazi Jewish, European (Finnish), European (non-Finnish) or Other populations. The p.Val211 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. |